Aims: HER2 is currently the only biomarker used to select eligible patients with advanced gastric cancer (GC) for targeted therapy. The aims of this study were to verify the value of dual-block HER2 assessment and to explore whether increasing the block number is more beneficial by carrying out a randomized prospective cohort study in which dual-block and all-block HER2 assessment were compared in resected specimens of GC. Methods and results: Five hundred and forty-nine resected GC specimens were randomly enrolled into two cohorts: a dual-block group (n = 274) with two primary tumour blocks tested, and an all-block group (n = 275) with all primary tumour blocks tested. Immunohistochemical staining of HER2 was performed. For HER2-equivocal (2+) cases, fluorescence in-situ hybridization (FISH) was performed. As compared with single-block assessment, dual-block assessment increased the HER2 immunohistochemistry (IHC)-positive (3+) rate. The rate with dual-block assessment (11.3%) was significantly higher than that with block 1 assessment (8.8%) (P = 0.016) and block 2 assessment (9.1%) (P = 0.031). Similarly, all-block assessment demonstrated a higher HER2 3+ rate (12.4%) than single-block assessment (block 1, 6.5%; block 2, 6.2%; block 3, 7.2%; block 4, 8.7%) (P < 0.05). HER2 3+ rates of all-block and dualblock assessments showed no significant difference (P = 0.703). After IHC and FISH results had been combined, the HER2-positive rate with all-block assessment (13.5%) was slightly higher than that with dual-block assessment (12.0%), although the difference was not statistically significant (P = 0.62). Conclusions: Dual-block immunohistochemical assessment is an effective, practical and economic approach that is suitable for the preliminary screening of HER2. We recommend that dual-block HER2 assessment be routinely performed on resected specimens of GC. All-block assessment can be a supplement to dual-block assessment if necessary. 
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Introduction
Gastric cancer (GC) is a major global health concern, with 952 000 new cases and 723 000 deaths occurring in 2012. 1 Although there have been declines in the incidence and mortality rates in recent years, it remains the fifth most common malignancy worldwide. 1, 2 In China, GC is the second and the third most common cancer among men and women, respectively, and it is the second leading cause of cancer death for both sexes. 3 The management of GC is complex and is evolving. 4 For advanced/metastatic tumours, the prognosis is dismal. 1, 5, 6 The 5-year survival rate for advanced GC patients is approximately 5-20%, and overall survival (OS) is~10 months for those who receive conventional chemotherapy. 7 Recently, molecular targeted therapy has been proven to improve the survival of advanced GC patients as a new strategy. 7 The ToGA trial showed that trastuzumab plus chemotherapy significantly improved the OS of human epidermal growth receptor 2 (HER2)-positive GC patients. 8 Since then, HER2 has become an established predictive biomarker for selecting patients eligible for this targeted therapy.
Several approaches can be used to evaluate HER2, including immunohistochemistry (IHC), 9 fluorescence in-situ hybridization (FISH), and silver in-situ hybridization (SISH). 10 Several GC-specific HER2 testing protocols based on these methodologies have been developed and standardized. 11, 12 Briefly, IHC is the initial testing method, and FISH/SISH should be used to retest IHC 2+ samples. 8, 11 Obtaining reliable IHC results is currently the top priority in HER2 assessment.
However, heterogeneous staining of HER2 is more common in GC than in breast cancer. [13] [14] [15] Heterogeneity was estimated to be present in 30-79.3% of HER2-positive GCs, 11, [15] [16] [17] and this may lead to falsenegative results. 18, 19 Thus, developing efficient methods to address this heterogeneity is a practical issue in the immunohistochemical analysis of HER2 in GC patients.
To cope with the heterogeneity, we were the first to propose conducting HER2 assessment on two tumour-containing blocks. 20 That retrospective study indicated that the HER2 3+ rate could be increased by using dual-block analysis rather than single-block analysis. Nevertheless, it is still unclear whether a further increase in the block number can provide additional benefit to HER2 assessment. Some researchers have tried to identify HER2 focal 3+ patients by performing HER2 immunohistochemical staining on all tumour blocks in a small number of selected patients. 21 Nevertheless, the value of HER2 assessment in more than two blocks remains to be elucidated.
Thus, in the current prospective study, we analysed and compared HER2 status between a cohort of patients assessed with two primary tumour blocks and a cohort assessed with all primary tumour blocks. The main aim of the study was to explore whether using more than two blocks in HER2 assessment is more beneficial in resected specimens of GC.
Materials and methods

P A T I E N T S
The research protocol was approved by the ethics board of Zhongshan Hospital, Fudan University (B2015-055R, 7 May 2015). From June 2015 to December 2015, resected samples of GC were prospectively obtained in the Pathology Department of Zhongshan Hospital. According to the study design, cases with the following conditions were excluded: special subtypes (adenosquamous carcinoma, squamous carcinoma, hepatoid adenocarcinoma, carcinoma with lymphoid stroma, and neuroendocrine tumours), having received neoadjuvant therapy before surgery, or the presence of multiple or recurrent tumours. Then, the included cases were randomly divided into either a cohort for which two primary tumour paraffin blocks (dual-block group) were used for assessment, or a cohort for which all available primary tumour blocks (all-block group) were used for assessment by the use of randomization tables. A total of 549 patients were enrolled in the study. Finally, 274 and 275 cases were assigned to the dual-block group and the allblock group, respectively. Prior written informed consent was obtained from all patients.
Patient characteristics, including age, sex, tumour location (proximal or distal), Lauren classification, 22 ,23 differentiation, 22 pTNM stage (according to the seventh edition of the Union for International Cancer Control guidelines), 24 tumour size, and numbers of primary tumour blocks, were collected.
S P E C I M E N H A N D L I N G A N D I M M U N O H I S T O C H E M I C A L S T A I N I N G
The specimens were fixed in 10% buffered formalin within 30 min after excision. Samples were processed with routine procedures after fixation for 24 h. The specimens were handled according to the guidelines recommended in Rosai and Ackerman's Surgical Pathology (10th edn). Haematoxylin and eosin (H&E) staining was routinely performed. An HER2 (4B5) rabbit monoclonal antibody (Ventana Medical Systems, Tucson, AZ, USA) was used, and immunohistochemical staining was performed with iView DAB Detection Kits (Ventana Medical Systems) on BenchMark XT automated stainers (Ventana Medical Systems), following previously described procedures.
All H&E sections were reviewed by two experienced gastrointestinal pathologists. Only primary tumours were subjected to HER2 detection. In the dual-block group, two tumour-containing blocks were selected for HER2 analysis. Blocks with the following characteristics were given priority in the selection: containing an intestinal-type component, showing the lowest grade, and rich in tumour cells. The two blocks were recorded as block 1 and block 2 according to the order of their serial numbers generated during pathological sampling. In the all-block group, HER2 IHC was performed on all primary tumour blocks. The blocks obtained for each case were also numbered consecutively on the basis of their serial numbers.
The HER2 status of each case was assessed by two independent observers. All observers were blinded with regard to the aim of the study. Cases with discrepant HER2 scores were further verified by a discussion panel including three observers. HER2 was assessed according to the established criteria for surgical specimens in GC. [25] [26] [27] Briefly, samples with no staining or positive staining of <10% of tumour cells were assigned a score of 0; samples with faintly or barely perceptible staining on ≥10% of the tumour cell membrane and in only part of the membrane were assigned a score of 1+; samples with weak to moderate complete, basolateral or lateral membranous reactivity in ≥10% of tumour cells were assigned a score of 2+; and samples with strong complete, basolateral or lateral membranous reactivity in ≥10% of tumour cells were assigned a score of 3+. HER2 status was scored on the basis of the staining patterns of individual blocks. Each block was scored and recorded. When there were discrepancies between or among the blocks in a single case, the highest score was recorded as the final score of the case. HER2 3+ was considered to be IHC-positive, 2+ was considered to be equivocal, and 0/1+ was considered to be HER2-negative.
In this study, intratumoral heterogeneity of HER2 was defined as the presence of discordant HER2 immunohistochemical expression (positive, equivocal, or negative) between or among the blocks in one case. When all of the blocks in a case showed concordant HER2 results, the case was considered to be homogeneous.
F I S H
FISH was performed on all of the HER2 2+ cases. IHC sections of each case were reviewed, and one block with the strongest HER2 intensity was selected for the FISH analysis. A Pathvysion HER2 DNA Probe Kit (Abbott Laboratories, Des Plaines, IL, USA) was used, according to the manufacturer's instructions. The sample was considered to be positive for HER2 amplification when a minimum of 20 cancer cell nuclei showed an HER2/centromeric probe 17 ratio of ≥2, or when HER2 signal clusters were observed. 
S T A T I S T I C S
Results
C L I N I C O P A T H O L O G I C A L C H A R A C T E R I S T I C S
The clinicopathological features of the 549 patients are shown in Table 1 . There were 274 patients in the dual-block group. The age range was 24-87 years (median, 64 years; mean, 62.96 years). The maximum diameter of the tumours ranged from 10 mm to 160 mm (median, 40 mm), with an average of 42.6 mm. The number of primary tumour blocks ranged from 3 to 11 (without 10), with a median of 4. The mean block number was 4.40.
There were 275 patients in the all-block group. The age range was 25-84 years (median, 63 years; mean, 61.37 years). The maximum diameter of the tumours ranged from 10 to 150 mm (median, [28] [29] [30] were generally balanced between the two groups. No significant differences were found for sex (P = 0.416), differentiation (P = 0.832), Lauren classification (P = 0.903), location (P = 0.283), pTNM stage (P = 0.696), mean block number (P = 0.382), or mean maximum tumour diameter (P = 0.454).
H E R 2 I M M U N O H I S T O C H E M I C A L S T A T U S I N T H E D U A L -B L O C K G R O U P
In the dual-block group, the numbers of cases with HER2 0, 1+, 2+ and 3+ were 66 (24.1%), 92 (33.6%), 85 (31.0%), and 31 (11.3%), respectively, when both blocks were analysed. The IHC results of single-block assessments are shown in Table 2 .
To verify the value of dual-block assessment, we compared the results of single-block assessment and dual-block assessment within the group. The HER2 3+ rate with dual-block analysis was significantly higher than that with block 1 (8.8%, P = 0.016) and block 2 (9.1%, P = 0.031) ( Figure 1A ; Table 2 ). In addition, dual-block assessment increased the HER2 2+ rate (P = 0.052 versus block 1; P < 0.001 versus block 2) and reduced the HER2-negative (0/1+) rate (P < 0.001 versus blocks 1 and 2) (Figure 1B,C; Table 2 ).
H E R 2 I M M U N O H I S T O C H E M I C A L S T A T U S I N T H E A L L -B L O C K G R O U P
In the all-block group, we evaluated and compared single-block assessment and all-block assessment. The numbers of patients with HER2 0, 1+, 2+ and 3+ were 41 (14.9%), 85 (30.9%), 115 (41.8%), and 34 (12.4%), respectively, when all blocks were analysed. Because there were only 62 cases with more than four blocks available, the HER2 status of single-block assessment was analysed in only the first four blocks. The results of single-block assessments are shown in Table 2 . The HER2 3+ rate with all-block assessment was significantly higher than that with single-block assessment (P < 0.001 versus blocks 1, 2, and 3; P = 0.002 versus block 4) (Table 2; Figure 1A ). Additionally, all-block assessment gave a much higher HER2 2+ rate (P < 0.001 versus blocks 1, 2, and 4; P = 0.001 versus block 3) and a much lower HER2-negative (0/1+) rate (P < 0.001 versus blocks 1, 2, 3, and 4) than did singleblock assessment (Figure 1B,C; Table 2 ).
I N T R A T U M O R A L H E T E R O G E N E I T Y I N T H E T W O G R O U P S
In both groups, some of the cases showed discordant (heterogeneous) HER2 staining between or among the analysed blocks ( Figure S1 ). In the dual-block group, 66 (24.1%) cases showed discordant HER2 staining between the two blocks. In the all-block group, 149 (54.2%) cases showed discordant HER2 results. Among the HER2 3+ cases, 13 (41.9%) cases in the dual-block group showed discordant HER2 staining between the two blocks, whereas, in the allblock group, 24 (70.6%) cases showed discordant HER2 staining.
The clinicopathological characteristics of the heterogeneous and homogeneous cases were further analysed and compared. The results showed no significant differences in sex (P = 0.633), differentiation (P = 0.150), Lauren classification (P = 0.289), tumour location (P = 0.096), stage (P = 0.214), or tumour size (P = 0.727), which indicated that it was not feasible to identify cases with HER2 heterogeneity on the basis of these clinicopathological features (Table 3) . 
C O M P A R I S O N O F H E R 2 I M M U N O H I S T O C H E M I C A L S T A T U S B E T W E E N T H E T W O G R O U P S
The HER2 3+ rate with single-block assessment (blocks 1 and 2) was first compared between the two groups. The dual-block group showed a slightly higher HER2 3+ rate than the all-block group, but the difference lacked statistical significance (P = 0.329 for block 1; P = 0.195 for block 2), underlying the importance of selecting appropriate blocks for HER2 assessment on the basis of histopathological characteristics (Table 2 ; Figure 1A) .
To explore whether all-block assessment was more beneficial than dual-block assessment, we compared the HER2 results between the two groups. The HER2 3+ rate of the all-block group (12.4%) was slightly higher than that of the dual-block group (11.3%), but the difference was not significant (P = 0.703) ( Figure 1A ; Table 2 ). In addition, the HER2 2+ rate of the all-block group (41.8%) was significantly higher than that of the dual-block group (31.0%) (P = 0.011) ( Figure 1B ; Table 2 ). The HER2 0/1+ rate of the allblock group (45.8%) was much lower than that of the dual-block group (57.7%) (P = 0.005) ( Figure 1C ; Table 2 ).
C O M P A R I S O N O F H E R 2 P O S I T I V I T Y B E T W E E N T H E T W O G R O U P S A F T E R F I S H
FISH analyses were performed on all of the 200 HER2-equivocal (2+) cases (dual-block group, 85 cases; all-block group, 115 cases). In total, five cases were identified as having HER2 amplification (Figure 2A-C) . Among them, two belonged to the dualblock group, and the other three to the all-block group. After the IHC and FISH results had been combined, 33 cases in the dual-block group were identified as HER2-positive (12.0%; 31 IHC 3+ and two IHC 2+/FISH-positive cases). In the all-block group, 37 cases were HER2-positive (13.5%; 34 IHC 3+ and 3 IHC 2+/FISH-positive cases). Although the HER2 positivity rate was slightly higher in the all-block group, there were no significant differences between the two groups (P = 0.62) ( Figure 2D ).
Discussion
Heterogeneous staining of HER2 is far more common in GC than in breast carcinomas. 14, 25, 27, 31 The heterogeneity adversely affects the accuracy of HER2 assessment, 32 and may lead to false-negative results. 28 In the current study, heterogeneity was identified in 41.9% (dual-block group) to 70.6% (allblock group) of the HER2 3+ cases. In addition, as indicated in this study, it is not possible to identify heterogeneous cases on the basis of the histopathological features. For such patients, routinely testing HER2 on a single block may lead to false-negative findings. It is of clinical importance to identify such heterogeneous cases, because focal HER2-positive patients may also benefit from trastuzumab therapy. 32, 33 In our previous study, we proposed that HER2 immunohistochemical positivity can be increased by conducting HER2 assessment on two tumour blocks. 20 The results of the current study were in line with previous findings. In both cohorts, multipleblock assessment increased the HER2 IHC-positive rate. Additionally, our results also demonstrated the importance of block selection based on the histopathological features in HER2 assessment, as indicated in a recent guideline. 12 To explore whether further increasing the block number would benefit HER2 assessment, we compared HER2 status between the groups. We found an increase in the HER2-positive rate in the all-block group as compared with the dual-block group, but the difference was not statistically significant (P = 0.62).
These findings confirmed the value of dual-block assessment. In addition, as indicated in our previous study, 20 if the two blocks are put on one slide, immunohistochemical tests for both blocks can be performed simultaneously without the consumption of extra reagents. Dual-block assessment is therefore an efficient and practical method for providing more accurate HER2 results without much additional effort or expense.
As compared with dual-block assessment, all-block assessment did not significantly increase the HER2-positive rate. Additionally, it will inevitably be costly and labour-intensive to test all blocks. In this study, 1188 and 115 tumour blocks were subjected to immunohistochemical and FISH testing, respectively, in the all-block group. In the dual-block group, the corresponding block numbers were 548 and 85. The cost and labour of all-block assessment were 2.2 times and 1.4 times as much as those of dual-block assessment in the immunohistochemical and FISH analyses, respectively. The cost and workload of testing all blocks would limit its application in the routine clinical setting.
In our department, dual-block immunohistochemical assessment has been routinely performed in the HER2 analysis of resected specimens of GC since we identified its advantage over single-block assessment. 20 Our experience indicates that it is a feasible, affordable and useful approach to overcome HER2 heterogeneity. All-block assessment may not be suitable for routine application. However, for patients with advanced GC with strong indications for trastuzumab therapy, allblock assessment can be applied when dual-block assessment indicates a negative result. This is because all-block assessment visually demonstrated a higher HER2-positive rate than dual-block assessment. Therefore, the possibility of missing eligible patients for the targeted therapy may be minimized.
In the current guidelines for HER2 assessment of GC, the number of biopsy specimens was discussed. 11, 21, 27, 34 However, for resected specimens, no consensus was reached regarding the most suitable number of tumour-containing blocks to be tested. We hope that the findings of the current study and our previous study 20 will provide useful and timely information for developing new strategies to overcome HER2 heterogeneity in future guidelines for GC.
Our study has several limitations. First, it was a single-institution study. Second, this study examined only resected specimens. Biopsy specimens, which are more frequently obtained from patients with inoperable or metastatic tumours, are beyond the scope of the research. Third, little is currently known about the impact of heterogeneity on the response of GC to trastuzumab.
In conclusion, this single-institution prospective cohort study shows that dual-block HER2 analysis is an effective and practical method for coping with the HER2 heterogeneity of GC. Therefore, we recommend that dual-block HER2 immunohistochemical assessment be performed routinely as a preliminary screening approach in resected specimens of GC. For advanced-stage patients with indications for trastuzumab treatment, all-block assessment can be used as a supplement to dual-block assessment to potentially reduce the false-negative rate.
